SavedAdd your journal

Journals / Gülhane Tıp Dergisi / 2022 / Cilt: 64 - Sayı: 1

Mehran risk score model for predicting contrast-induced nephropathy after cardiac resynchronization therapy in patients with heart failure

Mehmet ERDOĞAN
Mustafa KARANFİL
Mehmet Akif ERDOL
Ahmet ERTEM
Koray DEMİRTAŞ
Mustafa ÖZBAY
Çağrı YAYLA
Ahmet AKDİ
Ali Can ÖZKAN
Adnan Burak AKÇAY
Serkan TOPALOĞLU
Pages
40–46
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patients had New York Heart Association class II-IV disease, wide QRS in electrocardiogram (>130 ms), and diminished left ventricular ejection fraction (

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: Contrast-induced nephropathy (CIN) is a challenging condition after cardiac procedures.
📊
Key Findings & Data:Mehran risk score (MS) is a simple tool for predicting CIN.
💡
Conclusion & Impact:The patients had New York Heart Association class II-IV disease, wide QRS in electrocardiogram (>130 ms), and diminished left ventricular ejection fraction (
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aims: Contrast-induced nephropathy (CIN) is a challenging condition after cardiac procedures. Mehran risk score (MS) is a simple tool for predicting CIN. We investigated the role of MS to predict CIN development following cardiac resynchronization therapy (CRT) implantation in heart failure (HF) patients. Methods: This single-center, retrospective study included HF patients who underwent CRT implantation. The patients had New York Heart Association class II-IV disease, wide QRS in electrocardiogram (>130 ms), and diminished left ventricular ejection fraction (

🔖

Cite This Article

ERDOĞAN, M., KARANFİL, M., ERDOL, M. A., ERTEM, A., DEMİRTAŞ, K., ÖZBAY, M., YAYLA, Ç., AKDİ, A., ÖZKAN, A. C., AKÇAY, A. B., TOPALOĞLU, S. (2022). Mehran risk score model for predicting contrast-induced nephropathy after cardiac resynchronization therapy in patients with heart failure. Gülhane Tıp Dergisi, Cilt: 64 - Sayı: 1, 40–46. https://ajindex.com/articles/526738

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137:67-492
  2. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200
  3. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. 2007;297:2502-2514
  4. Boriani G, Diemberger I. Cardiac resynchronization therapy in the real world: need to focus on implant rates, patient selection, co-morbidities, type of devices, and complications. Eur Heart J. 2017;38:2129-2131
  5. Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation. 2011;123:1159-1166
  6. Bradley DJ. Combining resynchronization and defibrillation therapies for heart failure. JAMA. 2003;289:2719-2721
  7. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368- 375
  8. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-2264
  9. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med. 1990;89:615-620 10. Cowburn PJ, Patel H, Pipes RR, Parker JD. Contrast nephropathy post cardiac resynchronization therapy: an under-recognized complication with important morbidity. Eur J Heart Fail. 2005;7:899-903
  10. Kowalczyk J, Lenarczyk R, Kowalski O, et al. Contrastinduced acute kidney injury in patients undergoing cardiac resynchronization therapy-incidence and prognostic importance. Sub-analysis of data from randomized TRUST CRT trial. J Interv Card Electrophysiol. 2014;40:1-8
  11. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J